References
- Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83(4):735–743. doi:https://doi.org/10.1093/ajcn/83.4.735. Cited in: PMID: 16600922.
- Misiak M. Cancer cachexia. Contemp Oncol/Współczesna Onkologia. 2003;7(5):381–388.
- Jaeschke R, Gajewski P, O’Byrne PM. McMaster textbook of internal medicine. Krakow: Empednium; 2020.
- Baker Rogers J, Syed K, Minteer JF. Cachexia. Treasure Island (FL): StatPearls Publishing; 2020.
- T de Barros C, Rios AC, Alves TFR, Batain F, Crescencio KMM, Lopes LJ, Zielińska A, Severino P, G Mazzola P, Souto EB, et al. Cachexia: pathophysiology and ghrelin liposomes for nose-to-brain delivery. Int J Mol Sci. 2020;21(17):5974. Cited in: PMID: 32825177. doi:https://doi.org/10.3390/ijms21175974.
- Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A. Cancer cachexia-pathophysiology and management. J Gastroenterol. 2013;48(5):574–594. doi:https://doi.org/10.1007/s00535-013-0787-0. Cited in: PMID: 23512346.
- Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, Reddy K, Hastings S, Exterman M, Balducci L, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol. 2010;11(3–4):107–117. doi:https://doi.org/10.1007/s11864-010-0127-z. Cited in: PMID: 21128029.
- Hanna RM, Ghobry L, Wassef O, Rhee CM, Kalantar-Zadeh K. A practical approach to nutrition, protein-energy wasting, sarcopenia, and cachexia in patients with chronic kidney disease. Blood Purif. 2020;49(1–2):202–211. doi:https://doi.org/10.1159/000504240. Cited in: PMID: 31851983.
- Shen S, Liao Q, Liu J, Pan R, Lee SM, Lin L. Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism. J Cachexia Sarcopenia Muscle. 2019;10(2):429–444. Cited in: PMID: 30793539. doi:https://doi.org/10.1002/jcsm.12393.
- Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294–305. doi:https://doi.org/10.1159/000356760. Cited in: PMID: 24731978.
- Morley JE, Kalantar-Zadeh K, Anker SD. COVID-19: a major cause of cachexia and sarcopenia? J Cachexia Sarcopenia Muscle. 2020;11(4):863–865. doi:https://doi.org/10.1002/jcsm.12589. Cited in: PMID: 32519505
- Grossberg AJ, Scarlett JM, Marks DL. Hypothalamic mechanisms in cachexia. Physiol Behav. 2010;100(5):478–489. doi:https://doi.org/10.1016/j.physbeh.2010.03.011. Cited in: PMID: 20346963.
- Yeh SS, Schuster MW. Geriatric cachexia: the role of cytokines. Am J Clin Nutr. 1999;70(2):183–197. doi:https://doi.org/10.1093/ajcn.70.2.183. Cited in: PMID: 10426694.
- Agnieszka P, Barbara G. Wyniszczenie nowotworowe a starcza sarcopenia; Cancer cahexia and ageing sarcopenia. Gerontologia Polska. 2006;14:113–118.
- Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104(17):2034–2038. Cited in: PMID: 11673342. doi:https://doi.org/10.1161/hc4201.097836.
- Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR, Marcelli M. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 2005;90(5):2920–2926. doi:https://doi.org/10.1210/jc.2004-1788. Cited in: PMID: 15713718.
- Porporato PE. Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 2016;5:e200. doi:https://doi.org/10.1038/oncsis.2016.3. Cited in: PMID: 26900952.
- Onwuamaegbu ME, Henein M, Coats AJ. Cachexia in malaria and heart failure: therapeutic considerations in clinical practice. Postgrad Med J. 2004;80(949):642–649. doi:https://doi.org/10.1136/pgmj.2004.020891. Cited in: PMID: 15537847.
- Chang HR, Dulloo AG, Bistrian BR. Role of cytokines in AIDS wasting. Nutrition. 1998;14(11–12):853–863. doi:https://doi.org/10.1016/s0899-9007(98)00108-7. Cited in: PMID: 9834928.
- Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, Galizia G, Della-Morte D, Gargiulo G, Cacciatore F, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211. Cited in: PMID: 31947528. doi:https://doi.org/10.3390/nu12010211.
- Santo RCE, Fernandes KZ, Lora PS, Filippin LI, Xavier RM. Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018;9(5):816–825. doi:https://doi.org/10.1002/jcsm.12320. Cited in: PMID: 30133186.
- Scherbakov N, Pietrock C, Sandek A, Ebner N, Valentova M, Springer J, Schefold JC, Haehling S, Anker SD, Norman K, et al. Body weight changes and incidence of cachexia after stroke. J Cachexia Sarcopenia Muscle. 2019;10(3):611–620. Cited in: PMID: 30680953. doi:https://doi.org/10.1002/jcsm.12400.
- Subramaniam K, Fallon K, Ruut T, Lane D, McKay R, Shadbolt B, Ang S, Cook M, Platten J, Pavli P, et al. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn’s disease. Aliment Pharmacol Ther. 2015;41(5):419–428. doi:https://doi.org/10.1111/apt.13058. Cited in: PMID: 25580985.
- Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis. Int J Mol Sci. 2020;21(15):5254. Cited in: PMID: 32722100. doi:https://doi.org/10.3390/ijms21155254.
- Mücke M, Weier M, Carter C, Copeland J, Degenhardt L, Cuhls H, Radbruch L, Häuser W, Conrad R. Systematic review and meta-analysis of cannabinoids in palliative medicine. J Cachexia Sarcopenia Muscle. 2018;9(2):220–234. doi:https://doi.org/10.1002/jcsm.12273. Cited in: PMID: 29400010
- Badowski ME, Yanful PK. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag. 2018;14:643–651. Aprdoi:https://doi.org/10.2147/TCRM.S126849. Cited in: PMID: 29670357.
- Bodine M, Kemp AK. Medical cannabis use in oncology. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572067/
- Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438–2453. doi:https://doi.org/10.1200/JCO.20.00611. Cited in: PMID: 32432946.
- Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, Buonaccorso L, de van der Schueren MAE, Baldwin C, Chasen M, et al. Cancer cachexia in adult patients: ESMO clinical practice guidelines⋆. ESMO Open. 2021;6(3):100092. doi:https://doi.org/10.1016/j.esmoop.2021.100092. Cited in: PMID: 34144781.
- Wang J, Wang Y, Tong M, Pan H, Li D. Medical cannabinoids for cancer cachexia: a systematic review and meta-analysis. Biomed Res Int. 2019;2019:2864384. doi:https://doi.org/10.1155/2019/2864384. Cited in: PMID: 31341892.
- Turgeman I, Bar-Sela G. Cannabis for cancer - illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin Investig Drugs. 2019;28(3):285–296. doi:https://doi.org/10.1080/13543784.2019.1561859. Cited in: PMID: 30572744.
- Yoshida T, Tabony AM, Galvez S, Mitch WE, Higashi Y, Sukhanov S, Delafontaine P. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 2013;45(10):2322–2332. doi:https://doi.org/10.1016/j.biocel.2013.05.035. Cited in: PMID: 23769949.
- Clark AL, Coats AJS, Krum H, Katus HA, Mohacsi P, Salekin D, Schultz MK, Packer M, Anker SD. Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle. 2017;8(4):549–556. Cited in: PMID: 28244261. doi:https://doi.org/10.1002/jcsm.12191.
- Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, Beadle J, Anker SD. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7(3):355–365. doi:https://doi.org/10.1002/jcsm.12126. Cited in: PMID: 27386169.
- Prado BL, Qian Y. Anti-cytokines in the treatment of cancer cachexia. Ann Palliat Med. 2019;8(1):67–79. doi:https://doi.org/10.21037/apm.2018.07.06. Cited in: PMID: 30180740.
- Advani SM, Advani PG, VonVille HM, Jafri SH. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. BMC Cancer. 2018;18(1):1174. doi:https://doi.org/10.1186/s12885-018-5080-4. Cited in: PMID: 30482179.
- von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. 2014;15(12):866–872. doi:https://doi.org/10.1016/j.jamda.2014.09.007. Cited in: PMID: 25455531.
- Del Fabbro E. Combination therapy in cachexia. Ann Palliat Med. 2019;8(1):59–66. doi:https://doi.org/10.21037/apm.2018.08.05. Cited in: PMID: 30180745.
- Malik JS, Yennurajalingam S. Prokinetics and ghrelin for the management of cancer cachexia syndrome. Ann Palliat Med. 2019;8(1):80–85. doi:https://doi.org/10.21037/apm.2018.11.01. Cited in: PMID: 30525771.
- Fonseca GWPD, Haehling v. S. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia. Expert Opin Pharmacother. 2021;22(7):889–895. doi:https://doi.org/10.1080/14656566.2021.1873954. Cited in: PMID: 33491505.
- Saeteaw M, Sanguanboonyaphong P, Yoodee J, Craft K, Sawangjit R, Ngamphaiboon N, Shantavasinkul PC, Subongkot S, Chaiyakunapruk N. Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis. BMJ Support Palliat Care. 2021;11(1):75–85. doi:https://doi.org/10.1136/bmjspcare-2020-002601. Cited in: PMID: 33246937.
- Bertrand V, Massy N, Vegas N, Gras V, Chalouhi C, Tavolacci MP, Abadie V. Safety of cyproheptadine, an orexigenic drug. Analysis of the French national pharmacovigilance data-base and systematic review. Front Pediatr. 2021;9:712413. doi:https://doi.org/10.3389/fped.2021.712413. Cited in: PMID: 34676184.
- Davis MP. The emerging role of palliative medicine in the treatment of lung cancer patients. Cleve Clin J Med. 2012;79(Suppl 1):eS51–eS55. doi:https://doi.org/10.3949/ccjm.79.s2.11. Cited in: PMID: 22614967.
- Katzung BG, Masters SB, Trevor AJ. Basic & clinical pharmacology. 12th ed. New York (NY): McGraw-Hill Education; 2012.
- Bowen TS, Adams V, Werner S, Fischer T, Vinke P, Brogger MN, Mangner N, Linke A, Sehr P, Lewis J, et al. Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J Cachexia Sarcopenia Muscle. 2017;8(6):939–953. Cited in: PMID: 28887874. doi:https://doi.org/10.1002/jcsm.12233.
- Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531462/
- Liu L, Xu S, Wang X, Jiao H, Zhao J, Lin H. Effect of dexamethasone on hypothalamic expression of appetite-related genes in chickens under different diet and feeding conditions. J Anim Sci Biotechnol. 2016;7:23. doi:https://doi.org/10.1186/s40104-016-0084-x. Cited in: PMID: 27073616.
- Paulsen O, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, Kaasa S. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32(29):3221–3228. doi:https://doi.org/10.1200/JCO.2013.54.3926. Cited in: PMID: 25002731.
- Penedo-Vázquez A, Duran X, Mateu J, López-Postigo A, Barreiro E. Curcumin and resveratrol improve muscle function and structure through attenuation of proteolytic markers in experimental cancer-induced cachexia. Molecules. 2021;26(16):4904. Cited in: PMID: 34443492. doi:https://doi.org/10.3390/molecules26164904.
- Novelle MG, Wahl D, Diéguez C, Bernier M, de Cabo R. Resveratrol supplementation: where are we now and where should we go? Ageing Res Rev. 2015;21:1–15. doi:https://doi.org/10.1016/j.arr.2015.01.002. Cited in: PMID: 25625901.
- Musolino V, Palus S, Latouche C, Gliozzi M, Bosco F, Scarano F, Nucera S, Carresi C, Scicchitano M, von Haehling S, et al. Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy. ESC Heart Fail. 2019;6(1):89–97. Feb Cited in: PMID: 30367561. doi:https://doi.org/10.1002/ehf2.12372.
- Ruiz-García V, López-Briz E, Carbonell-Sanchis R, Bort-Martí S, Gonzálvez-Perales JL. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle. 2018;9(3):444–452. doi:https://doi.org/10.1002/jcsm.12292. Cited in: PMID: 29542279.
- Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr. 2010;91(4):1143S–1147S. doi:https://doi.org/10.3945/ajcn.2010.28608E. Cited in: PMID: 20164318.
- Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res. 1997;17(1B):657–662. Cited in: PMID: 9066597.
- R, Garcia V, López-Briz E, Carbonell SR, Gonzalvez PJ, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013:CD004310. doi:https://doi.org/10.1002/14651858.CD004310.pub3.Cited in: PMID: 23543530.
- Currow DC, Glare P, Louw S, Martin P, Clark K, Fazekas B, Agar MR. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep. 2021;11(1):2421. doi:https://doi.org/10.1038/s41598-021-82120-8. Cited in: PMID: 33510313.
- Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM, Jr, Camoriano JK, Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17(10):3299–3306. doi:https://doi.org/10.1200/JCO.1999.17.10.3299. Cited in: PMID: 10506633.
- Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Dessì M, Panzone F, Contu P. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist. 2010;15(2):200–211. doi:https://doi.org/10.1634/theoncologist.2009-0153. Cited in: PMID: 20156909.
- Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev. 2006;15(5):1030–1034. doi:https://doi.org/10.1158/1055-9965.EPI-05-0538. Cited in: PMID: 16702388.
- Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001;12(3):289–300. Cited in: PMID: 11332139. doi:https://doi.org/10.1023/A:1011156811739.
- Kurebayashi J, Yamamoto S, Otsuki T, Sonoo H. Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer. 1999;79(3–4):631–636. doi:https://doi.org/10.1038/sj.bjc.6690099. Cited in: PMID: 10027341.
- Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, Erdkamp FL, Cobben EG, Schoon EJ, Smeets JB, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol. 1996;14(4):1077–1084. doi:https://doi.org/10.1200/JCO.1996.14.4.1077. Cited in: PMID: 8648360.
- Basaria S, Wahlstrom JT, Dobs AS. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab. 2001;86(11):5108–5117. doi:https://doi.org/10.1210/jcem.86.11.7983. Cited in: PMID: 11701661.
- Osmolak AM, Klatt-Cromwell CN, Price AM, Sanclement JA, Krempl GA. Does perioperative oxandrolone improve nutritional status in patients with cachexia related to head and neck carcinoma? Laryngoscope Investig Otolaryngol. 2019;4(3):314–318. doi:https://doi.org/10.1002/lio2.268. Cited in: PMID: 31236465.
- Borst SE, Shuster JJ, Zou B, Ye F, Jia H, Wokhlu A, Yarrow JF. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014;12:211. doi:https://doi.org/10.1186/s12916-014-0211-5.
- Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS. 1996;10(14):1657–1662. doi:https://doi.org/10.1097/00002030-199612000-00010. Cited in: PMID: 8970686.
- Cuerda C, Zugasti A, Bretón I, Camblor M, Miralles P, García P. Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men. Nutr Clin Pract. 2005;20(1):93–97. Cited in: PMID: 16207650. doi:https://doi.org/10.1177/011542650502000193.
- Lydén E, Cvetkovska E, Westin T, Oldfors A, Soussi B, Gustafsson B, Edström S. Effects of nandrolone propionate on experimental tumor growth and cancer cachexia. Metabolism. 1995;44(4):445–451. doi:https://doi.org/10.1016/0026-0495(95)90050-0. Cited in: PMID: 7723666.
- Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247–1264. Jundoi:https://doi.org/10.1517/14656566.2014.913022. Cited in: PMID: 24758365.
- Somboonporn W. Testosterone therapy for postmenopausal women: efficacy and safety. Semin Reprod Med. 2006;24(2):115–124. Aprdoi:https://doi.org/10.1055/s-2006-939570. Cited in: PMID: 16633985.
- Islam RM, Bell RJ, Green S, Davis SR. Effects of testosterone therapy for women: a systematic review and meta-analysis protocol. Syst Rev. 2019;8(1):19. Jan 11doi:https://doi.org/10.1186/s13643-019-0941-8. Cited in: PMID: 30635029.
- Rybaczyk LA, Bashaw MJ, Pathak DR, Moody SM, Gilders RM, Holzschu DL. An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology . BMC Womens Health. 2005;5:12. doi:https://doi.org/10.1186/1472-6874-5-12. Cited in: PMID: 16368009.
- Mela V, Vargas A, Meza C, Kachani M, Wagner EJ. Modulatory influences of estradiol and other anorexigenic hormones on metabotropic, Gi/o-coupled receptor function in the hypothalamic control of energy homeostasis. J Steroid Biochem Mol Biol. 2016;160:15–26. doi:https://doi.org/10.1016/j.jsbmb.2015.07.014. Cited in: PMID: 26232394.
- Counts BR, Fix DK, Hetzler KL, Carson JA. The effect of estradiol administration on muscle mass loss and cachexia progression in female ApcMin/+ mice. Front Endocrinol (Lausanne). 2019;10:720. doi:https://doi.org/10.3389/fendo.2019.00720. Cited in: PMID: 31736871.
- Delgado BJ, Lopez-Ojeda W. Estrogen. Treasure Island (FL): StatPearls Publishing; 2022. Jan.
- Paredes S, Cantillo S, Candido KD, Knezevic NN. An association of serotonin with pain disorders and its modulation by estrogens. IJMS. 2019;20(22):5729. Cited in: PMID: 31731606. doi:https://doi.org/10.3390/ijms20225729.
- Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84–94. doi:https://doi.org/10.1016/j.sxmr.2018.09.006. Cited in: PMID: 30503797.
- Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013;7(4):345–351. doi:https://doi.org/10.1097/SPC.0000000000000015. Cited in: PMID: 24189892.
- Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, Johnston MA, Steiner MS. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–345. doi: https://doi.org/10.1016/S1470-2045(13)70055-X. Cited in: PMID: 23499390.
- Mehrzad V, Afshar R, Akbari M. Pentoxifylline treatment in patients with cancer cachexia: a double-blind, randomized, placebo-controlled clinical trial. Adv Biomed Res. 2016;5:60. doi:https://doi.org/10.4103/2277-9175.179182. Cited in: PMID: 27135029.
- McKeaveney C, Maxwell P, Noble H, Reid J. A critical review of multimodal interventions for cachexia. Adv Nutr. 2021;12(2):523–532. Mar 31doi:https://doi.org/10.1093/advances/nmaa111. Cited in: PMID: 32970097.
- Serna-Thomé G, Castro-Eguiluz D, Fuchs-Tarlovsky V, Sánchez-López M, Delgado-Olivares L, Coronel-Martínez J, Molina-Trinidad EM, de la Torre M, Cetina-Pérez L. Use of functional foods and oral supplements as adjuvants in cancer treatment. Rev Invest Clin. 2018;70(3):136–146. doi:https://doi.org/10.24875/RIC.18002527. Cited in: PMID: 29943769.
- Oliveira EA, Zheng R, Carter CE, Mak RH. Cachexia/protein energy wasting syndrome in CKD: causation and treatment. Semin Dial. 2019;32(6):493–499. doi:https://doi.org/10.1111/sdi.12832. Cited in: PMID: 31286575.
- Cederholm T, Barazzoni R, Austin P, Ballmer P, Biolo G, Bischoff SC, Compher C, Correia I, Higashiguchi T, Holst M, et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr. 2017;36(1):49–64. doi:https://doi.org/10.1016/j.clnu.2016.09.004. Cited in: PMID: 27642056.
- Argilés JM, López-Soriano FJ, Stemmler B, Busquets S. Therapeutic strategies against cancer cachexia. Eur J Transl Myol. 2019;29(1):7960. doi:https://doi.org/10.4081/ejtm.2019.7960. Cited in: PMID: 31019661.
- Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E. Holland-Frei cancer medicine. 6th ed. Hamilton (ON): BC Decker; 2003.
- MochamatCuhls H, Marinova M, Kaasa S, Stieber C, Conrad R, Radbruch L, Mücke M. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle. 2017;8:25–39. doi:https://doi.org/10.1002/jcsm.12127. Cited in: PMID: 27897391.
- Okoshi MP, Capalbo RV, Romeiro FG, Okoshi K. Cardiac cachexia: perspectives for prevention and treatment. Arq Bras Cardiol. 2017;108(1):74–80. doi:https://doi.org/10.5935/abc.20160142. Cited in: PMID: 27812676.